Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05192200
Study type Interventional
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email [email protected]
Status Recruiting
Phase Phase 2
Start date December 20, 2021
Completion date October 10, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04972760 - Baricitinib in Patients With Relapsing or naïve Dermatomyositis Phase 3
Completed NCT01906372 - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Phase 2
Completed NCT01813617 - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Not yet recruiting NCT05027152 - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties N/A
Recruiting NCT04723303 - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) Early Phase 1
Recruiting NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT04044690 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) Phase 3
Recruiting NCT03324152 - Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT02043548 - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Phase 2
Active, not recruiting NCT03414086 - Predictor of Clinical Response to Acthar in Myositis
Enrolling by invitation NCT04628936 - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. Phase 2
Recruiting NCT03293615 - Exercise Capacity of Patients With Dermatomyosis N/A
Completed NCT02594735 - Abatacept in Juvenile Dermatomyositis Phase 4
Completed NCT02612857 - Trial of IMO-8400 in Adult Patients With Dermatomyositis Phase 2
Terminated NCT02271165 - Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study Early Phase 1
Completed NCT00213629 - myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies N/A
Completed NCT00010335 - Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Phase 1
Active, not recruiting NCT02971683 - Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Phase 3